Products

Zanolimumab (TAB-039)

Recombinant monoclonal antibody to CD4. Zanolimumab (expected trade name HuMax-CD4) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma.      

  • Published Data
  • Datasheet

Figure 1 Zanolimumab selectively kills CD4+ T cells by ADCC.

A, zanolimumab does not fix complement factor C4 when bound to CD4+ T cells. Zanolimumab bound to cells does not induce complement activation as measured by deposition of C4. Representative of three independent experiments. The CD4+CD45RA+ T-cell population (left) and the CD4+CD45RO+ T-cell population (right) were measured using anti-CD45RA+-PE and CD45RO+-APC antibodies. The antibody OKT3, as positive control at the same concentrations, does induce C4 deposition. B, zanolimumab kills CD4+ T cells via ADCC. CD4+ T cells are efficiently killed by NK cell–dependent ADCC (left). Left, histograms of the CD4+ T cells. Columns, mean of four independent experiments; bars, SE. Right, histograms of the CD4+CD45RA+ and CD4+CD45RO+ T cells. Columns, mean of nine independent experiments; bars, SE. **, P < 0.005, Wilcoxon signed-rank test, CD4+CD45RO+ specific lysis by zanolimumab differs significantly from CD45+CD45RA+ specific lysis.

Rider, D. A., Havenith, C. E., de Ridder, R., Schuurman, J., Favre, C., Cooper, J. C., ... & Cambier, J. (2007). A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer research, 67(20), 9945-9953.

Figure 2 Zanolimumab down-modulates CD4 expression.

A, dose-response plots of CD4 expression were carried out using purified blood CD4+ T cells incubated for 18 h with zanolimumab in the presence or absence of monocytes (Mo) incubated with or without IFNγ. B, dose-response plots of CD4 expression were carried out using CD4+ CEM-NKr cells incubated for 18 h with zanolimumab, F(ab′)2 fragments of zanolimumab, or an isotype control antibody (HuMab-KLH) in the presence or absence of THP-1 cells. The CD4 expression levels were measured using a noncompeting CD4 antibody, MT-477. Results are representative of four different experiments.

Rider, D. A., Havenith, C. E., de Ridder, R., Schuurman, J., Favre, C., Cooper, J. C., ... & Cambier, J. (2007). A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer research, 67(20), 9945-9953.

Figure 3 Zanolimumab inhibits T-cell activation.

A, dose-response plots of proliferation assays were carried out using purified CD4+ T cells stimulated with tetanus toxoid (TT; 10 μg/mL) at the concentrations shown. Points, mean of two independent experiments; bars, SE. B, dose-response plots of proliferation assays were carried out using purified CD4+ T cells stimulated with immobilized OKT3 mAb (0.1 μg/mL) coated onto latex beads, either with or without the addition of anti-CD28 (1.0 μg/mL) at the concentrations shown. Points, mean of four independent experiments; bars, SE. C, supernatants removed from proliferation assays after 48 h were assayed for IL-2 and IL-4. Points, mean of four independent experiments; bars, SE.

Rider, D. A., Havenith, C. E., de Ridder, R., Schuurman, J., Favre, C., Cooper, J. C., ... & Cambier, J. (2007). A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer research, 67(20), 9945-9953.

Figure 4 Zanolimumab inhibits initiation of TCR signal transduction and downstream signals in CD4+ T cells.

Purified CD4+ T cells were incubated with (+) or without (−) zanolimumab for 10 min before incubation with mouse IgG1 (0 min) or OKT3-coated latex beads at 37°C for the times shown. Cells were lysed before samples were split into two and proteins were separated by 7% to 15% gradient SDS-PAGE. A, one membrane was then immunoblotted with the phosphotyrosine mAb 4G10 before stripping (top) and reprobing with LAT (middle) and TCRζ antibodies (bottom). B and C, the second membrane was probed with phospho-ZAP-70 (B) and phospho-Erk1/2 antibodies, phospho-p38, and phospho-AKT (C) and followed by stripping and reprobing with ZAP-70, Erk1/2, p38, and AKT, respectively, to assess loading. Results for the experiments are representative of four different experiments.

Rider, D. A., Havenith, C. E., de Ridder, R., Schuurman, J., Favre, C., Cooper, J. C., ... & Cambier, J. (2007). A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer research, 67(20), 9945-9953.

Figure 5 Zanolimumab induces p56lck-dependent phosphorylation of Dok-1 and SHIP-1.

A, CD4-associated p56lck tyrosine kinase activity is increased after CD4 ligation. Purified CD4+ T cells were incubated with zanolimumab, and CD4 was then immunoprecipitated from cell lysates, followed by in vitro kinase assays in the presence of α-casein before transfer to an immunoblotting membrane. CD4-p56lck autophosphorylation (top) and phosphorylated α-casein (middle top). Membranes were blotted for pY-394-p56lck and stripped and reprobed for both p56lck and CD4 as loading controls (middle, middle bottom, and bottom). B, Dok-1 phosphorylation is increased after CD4 ligation. Cells treated with zanolimumab were lysed and precleared with glutathione agarose beads coupled to an empty GST construct before Dok-1 was precipitated using a GST construct of the COOH-terminal SH2 domain of RasGAP (SH2C-RasGAP-GST). Samples were blotted with Dok-1 and GST antibody. C, SHIP-1 phosphorylation is increased after CD4 ligation. Cells were treated with either 10 μg/mL zanolimumab for 10 min before immunoblotting whole-cell lysates with a phosphospecific SHIP-1 antibody. D, phosphorylation of Dok-1 is dependent on the action of Src family kinases. CD4+ T cells were preincubated with the Src family inhibitors PP2 or damnacanthal (DAM) for 45 min before treatment with zanolimumab for 5 min and Dok-1 phosphorylation was then measured as in C. Results are representative of four different experiments.

Rider, D. A., Havenith, C. E., de Ridder, R., Schuurman, J., Favre, C., Cooper, J. C., ... & Cambier, J. (2007). A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer research, 67(20), 9945-9953.


Specifications
Immunogen
The details of the immunogen for this antibody are not available.
Host
Human
Derivation
Human
Type
IgG1 - kappa
Specificity
Tested positive against native human antigen.
Species Reactivity
Human
Applications
Neut, ELISA, IF, IP, FuncS, FC, IHC
Trade name
humax-cd4
CAS NO.
652153-01-0
Generic Name
Zanolimumab
UNII
HG3L8885M0
M.W.
147 kDa
Related Disease
Cutaneous T cell lymphoma (CTCL)
Applications
Application Notes
The CD4 antibody has been reported in applications of ADCC, FC, Inhib, WB, IP.
FC: effector cells were added to an effector cell:target cell ratio of 10:1, 5:1, or 4:1. IFNγ (concentration range, 125–1,000 μg/mL) was added and cells were incubated overnight. Cells were stained for CD4 with fluorochrome-labeled M-T477 and a target cell selection marker. Cell-associated fluorescence was assessed by flow cytometry.
IP: CD4+ T cells (1 × 107 for whole-cell lysates or 3 × 107 for immunoprecipitates) were preincubated with 20 μg/mL zanolimumab for 10 min at 37°C. Cells were washed once before stimulation with 10 μg/mL anti-CD3 mAb (OKT3) or isotype control immobilized onto 0.1-μm latex beads at 37°C for the indicated time points.
Target
Alternative Names
Zanolimumab; humax-cd4; 652153-01-0; 6G5.2; HuMax-CD4; CD4; CD4 molecule; CD4 antigen (p55) , T cell surface glycoprotein CD4
Entrez Gene ID
920
UniProt ID
P01730

For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Send Inquiry Now!
Name:
* Phone:
* E-mail Address:
* Service & Products Interested:
Project Description:
* Verification Code:
Verification code
Click image to refresh the verification code.

Contact Us to Order
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Increase Efficiency to Accelerate Your Research & Discovery Process

Increase Efficiency to Accelerate Your Research & 
Discovery Process

Creative Biolabs is the leading custom service provider that has extensive experience in various antibody production and engineering fields. Our service portfolio includes mouse and rat monoclonal antibody production ...

Find out more >

USA

45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356

Europe

Tel: 44-207-097-1828
Email:
Follow us on:
        

Terms of Service-Privacy Policy     © 2007 - 2019 Creative-Biolabs All Rights Reserved